Skymap Pharmaceuticals Acquires Indian Medicines Pharma for ₹121 Crore
Skymap Pharma to buy state-run Indian Medicines Pharma for Rs 121 crore
The Economic Times
Image: The Economic Times
The Indian government has approved the sale of Indian Medicines Pharmaceutical Corporation (IMPCL) to Skymap Pharmaceuticals for ₹121 crore. This marks the first strategic sale of a state-run entity since 2025.
- 01Skymap Pharmaceuticals won the bid for a 100% equity stake in IMPCL.
- 02The sale was approved by an inter-ministerial panel including key ministers.
- 03The Department of Investment and Public Asset Management will oversee the transaction's completion.
- 04The sale represents a significant move in India's privatization efforts.
- 05This is the first strategic sale since the 2025 sale of Ferro Scrap Nigam.
Advertisement
In-Article Ad
The Indian government has sanctioned the strategic sale of the state-run Indian Medicines Pharmaceutical Corporation (IMPCL) to Skymap Pharmaceuticals for ₹121 crore. An inter-ministerial panel, which included Finance Minister Nirmala Sitharaman and Ayush Minister Prataprao Ganpatrao Jadhav, approved Skymap's bid for full ownership and management control of IMPCL. The finance ministry confirmed that the letter of award has been issued to Skymap, with officials authorized to expedite the transaction. This sale is notable as it is the first strategic divestment of a state-run company since the sale of Ferro Scrap Nigam to Japan's Konoike Transport in FY25.
Advertisement
In-Article Ad
The sale could lead to operational changes and efficiency improvements in IMPCL under private management.
Advertisement
In-Article Ad
Reader Poll
Should the government sell state-run entities to private companies?
Connecting to poll...
Read the original article
Visit the source for the complete story.